Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.68
+0.03 (1.13%)
Market open: Aug 12, 2026, 10:01 AM EDT
2.71
+0.06 (2.26%)
Previous after-hours: Aug 11, 2026, 4:10 PM EDT
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company’s lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
There is no data to display
| Date | Type | Document |
|---|---|---|
| 2026-08-05 | 6-K | ea0300815-6k_xtlbiophar.htm |
| 2026-07-21 | 6-K | ea0298779-6k_xtlbio.htm |
| 2026-06-30 | 20-F | ea0296095-20f_xtlbio.htm |
| 2026-06-29 | 6-K | ea0296376-6k_xtlbio.htm |
| 2026-06-23 | 6-K | ea0295469-6k_xtlbio.htm |
| 2026-05-22 | 6-K | ea0291904-6k_xtlbio.htm |
| 2026-05-15 | 6-K | ea0291180-6k_xtlbio.htm |
| 2026-05-07 | 6-K | ea0289561-6k_xtlbio.htm |
| 2026-04-29 | 6-K | ea0288126-6k_xtlbio.htm |
| 2026-03-10 | 6-K | ea0280782-6k_xtlbio.htm |